ClinicalTrials.gg
RecruitingNCT07724041Updated Oct 5, 2026

Feasibility of a Real-world, Financial Psycho-oncology Intervention to Address Cancer-related Financial Distress

An interventional study of Financial psycho-oncology intervention in Cancer, Financial Hardship and Psychological Distress, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 5, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this pilot, feasibility study is to evaluate the feasibility and preliminary impact of a finance-specific psycho-oncology intervention, as well as to explore perceptions of and experiences with this financial psycho-oncology intervention for patients with cancer experiencing financial hardship. The main questions it aims to answer are:

  1. Is this financial psycho-oncology intervention feasible, acceptable, and appropriate for patients with cancer experiencing financial hardship?
  2. How can we refine the financial psycho-oncology intervention to best address financial distress for patients with cancer experiencing financial hardship?

Patients enrolled in the intervention will receive 2, 60-minute long, finance-specific psycho-oncology sessions per month over the course of 3 months, for a total of 6 sessions over the course of the intervention. Patients will complete surveys during intervention enrollment and after intervention completion to assess secondary outcomes of financial hardship, psychological distress, stress, and anxiety. Individuals who consent to the financial psycho-oncology intervention will also be invited to participate in a 30-minute semi-structured interview to explore their perceptions of and experiences with the financial psycho-oncology intervention, including concepts of participation and engagement, relevance and acceptability, content and understanding, logistics and practicality, and potential impact.

02

Conditions studied

  • Cancer
  • Financial Hardship
  • Psychological Distress
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with cancer receiving treatment at the UAB Medical Oncology and/or UAB Supportive Care clinics

Exclusion criteria

Exclusion Criteria:

  • non-English speakers
  • patients with non-melanoma skin cancers
  • patients with dementia/cognitive impairments
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patients receiving financial psycho-oncology intervention

    Behavioral: Financial psycho-oncology intervention

Interventions

  • BehavioralFinancial psycho-oncology intervention

    Program which integrates emotional support, coping strategies, and financial psychoeducation to enhance patients' capacity to cope with both their emotional and financial burdens due to cancer.

06

What researchers measure

Primary outcomes

  1. Recruitment as a measure of feasibility

    50% of contacted patients consenting to participate

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  2. Retention as a measure of feasibility

    70% of consenting patients completing the program per protocol

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  3. Completion as a measure of feasibility

    \<15% missing survey data

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

Secondary outcomes

  1. Change in Financial hardship

    as measured by COmprehensive Score for financial Toxicity (COST)

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  2. Change in Psychological distress

    as measured by National Comprehensive Cancer Network Distress Thermometer and Problem List

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  3. Change in Perceived stress

    as measured by Perceived Stress Scale (PSS-10)

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  4. Change in Anxiety

    as measured by PROMIS Emotional Distress - Anxiety - Short Form 4

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

  5. Change in Depression

    as measured by PROMIS Emotional Distress - Depression - Short Form 4

    Time frame: From enrollment to the end of the financial psycho-oncology intervention at 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 8 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 23, 2026
StartActual
Sep 1, 2026
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
University of Alabama at Birmingham is now Recruiting
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    University of Alabama at Birmingham is now Recruiting
    + 3 other changes: verification date, date precision and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07724041
Responsible party
Courtney Williams (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Jul 23, 2026
Start date
Sep 1, 2026
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Hayden Reeves
Contact
haydenreeves@uabmc.edu
205-996-4109
Courtney Williams, DrPH
principal investigator · University of Alabama at Birmingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion